Armatus Bio
Recent Finacing
Equity
Recent Raise
$3M
Armatus Bio develops vectorized RNAi gene therapies using AAV capsids (e.g., AAV‑SLB101) for genetically driven neuromuscular diseases, including ARM‑201 targeting DUX4 in FSHD and ARM‑101 for CMT1A.
